Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | AURKA | O14965 | 1/20 | 0.49 |
| ▸ | AURKB | Q96GD4 | 1/20 | 0.49 |
| ▸ | OPRK1 | P41145 | 1/20 | 0.44 |
| ▸ | CYP4F2 | P78329 | 1/20 | 0.41 |
| ▸ | CYP4A11 | Q02928 | 1/20 | 0.41 |
| ▸ | GSK3B | P49841 | 1/20 | 0.40 |
| ▸ | ITK | Q08881 | 4/20 | 0.39 |
| ▸ | CNR1 | P21554 | 1/20 | 0.37 |
| ▸ | CNR2 | P34972 | 1/20 | 0.37 |
| ▸ | PDGFRB | P09619 | 1/20 | 0.37 |
| ▸ | PDGFRA | P16234 | 1/20 | 0.37 |
| ▸ | ATP4A | P20648 | 4/20 | 0.36 |
| ▸ | ATP4B | P51164 | 4/20 | 0.36 |
| ▸ | IDO1 | P14902 | 2/20 | 0.36 |
| ▸ | EBP | Q15125 | 1/20 | 0.36 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.36 |
| ▸ | CYP19A1 | P11511 | 1/20 | 0.36 |
| ▸ | NPC1 | O15118 | 1/20 | 0.35 |
| ▸ | RAB9A | P51151 | 1/20 | 0.35 |
| ▸ | NLRP3 | Q96P20 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4120358 | 0.90 | AURKA (0.46) | AURKAAURKBOPRK1CYP4F2CYP4A11 | |
| SCHEMBL4118654 | 0.87 | AURKA (0.48) | AURKAAURKBGSK3BITK | |
| SCHEMBL4112674 | 0.82 | ITK (0.51) | AURKAAURKBITKNPC1RAB9A | |
| SCHEMBL13650124 | 0.80 | OPRK1 (0.45) | AURKAAURKBOPRK1CYP4F2CYP4A11 | |
| SCHEMBL5743306 | 0.77 | LMNA (0.43) | AURKAAURKBITKCNR2NPC1 | |
| SCHEMBL4120357 | 0.76 | AURKA (0.49) | AURKAAURKBGSK3BITKATP4A | |
| SCHEMBL4119607 | 0.70 | BCL2 (0.46) | — | |
| SCHEMBL18443835 | 0.69 | AURKA (0.45) | AURKAAURKBPDGFRBPDGFRAIDO1 | |
| SCHEMBL13650126 | 0.67 | ITK (0.44) | AURKAAURKBITKIDO1 | |
| SCHEMBL11698946 | 0.66 | NPC1 (0.67) | OPRK1CYP19A1NPC1RAB9ACHEK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090253697-A1 | Novel Indole Derivatives, Preparation Thereof as Medicinal Products and Pharmaceutical Compositions, and Especially as KDR Inhibitors | AVENTIS PHARMA S.A. (FR) | 2009-10-08 | — | — | US | claimed |
| EP-1633738-A2 | NOVEL INDOLE DERIVATIVES, METHOD OF PREPARING SAME IN THE FORM OF MEDICAMENTS, PHARMACEUTICAL COMPOSITIONS AND, IN PARTICULAR, KDR INHIBITORS | Aventis Pharma S.A. (FR) | 2006-03-15 | — | — | EP | claimed |
| US-20040242559-A1 | Novel indole derivatives, preparation thereof as medicinal products and pharmaceutical compositions, and especially as KDR inhibitors | AVENTIS PHARMA S.A. (FR) | 2004-12-02 | — | — | US | claimed |
| WO-2004096792-A2 | NOVEL INDOLE DERIVATIVES, METHOD OF PREPARING SAME IN THE FORM OF MEDICAMENTS, PHARMACEUTICAL COMPOSITIONS AND, IN PARTICULAR, KDR INHIBITORS | AVENTIS PHARMA S.A. (FR) | 2004-11-11 | — | — | WO | claimed |
| US-20090253697-A1 | Novel Indole Derivatives, Preparation Thereof as Medicinal Products and Pharmaceutical Compositions, and Especially as KDR Inhibitors | AVENTIS PHARMA S.A. (FR) | 2009-10-08 | — | — | US | disclosed |
| EP-1633738-A2 | NOVEL INDOLE DERIVATIVES, METHOD OF PREPARING SAME IN THE FORM OF MEDICAMENTS, PHARMACEUTICAL COMPOSITIONS AND, IN PARTICULAR, KDR INHIBITORS | Aventis Pharma S.A. (FR) | 2006-03-15 | — | — | EP | disclosed |
| US-20040242559-A1 | Novel indole derivatives, preparation thereof as medicinal products and pharmaceutical compositions, and especially as KDR inhibitors | AVENTIS PHARMA S.A. (FR) | 2004-12-02 | — | — | US | disclosed |
| WO-2004096792-A2 | NOVEL INDOLE DERIVATIVES, METHOD OF PREPARING SAME IN THE FORM OF MEDICAMENTS, PHARMACEUTICAL COMPOSITIONS AND, IN PARTICULAR, KDR INHIBITORS | AVENTIS PHARMA S.A. (FR) | 2004-11-11 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040242559-A1 | Novel indole derivatives, preparation thereof as medicinal products and pharmaceutical compositions, and especially as KDR inhibitors | FLT4, KDR, CYP3A4 | AURKA 1176/4885AURKB 1606/4885OPRK1 61/4885 |
| US-20090253697-A1 | Novel Indole Derivatives, Preparation Thereof as Medicinal Products and Pharmaceutical Compositions, and Especially as KDR Inhibitors | KDR, FLT1, FLT4 | AURKA 917/4885AURKB 558/4885OPRK1 110/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.